# Electrical stimulation: a novel adjunct therapy for diabetic foot ulcers

**Authors:** Yuanjun Liu, Xiaoyu Liu, Jin Lu, Yunnan Jiang, Jian Wu

PMC · DOI: 10.3389/fcdhc.2025.1682871 · Frontiers in Clinical Diabetes and Healthcare · 2026-01-07

## TL;DR

Electric stimulation is a promising new treatment for diabetic foot ulcers that helps speed up healing and reduce recurrence.

## Contribution

The paper reviews novel mechanisms and technologies in electrical stimulation as an adjunct therapy for diabetic foot ulcers.

## Key findings

- Electric stimulation promotes wound healing by guiding cell migration and proliferation.
- Cathodal currents reduce inflammation and support macrophage transition to a pro-healing state.
- New technologies like smart bandages are enabling home-based electrical stimulation therapy.

## Abstract

Diabetic foot ulcer (DFU) is one of the most severe complications of diabetes; its healing is typically protracted and marked by a high rate of recurrence. In recent years, electrical-stimulation (ES) therapy has emerged as a novel adjunct to conventional approaches such as debridement, negative-pressure wound therapy, and moist dressings. By applying an exogenous electric field that mimics the skin’s endogenous wound currents, ES provides directional cues for cells and signaling molecules involved in repair, guiding them toward the wound bed. The external field reconstructs the bioelectric landscape, inducing oriented migration and proliferation of keratinocytes, fibroblasts, and endothelial cells, while up-regulating factors such as HIF-1α and VEGF to relieve local ischemia and promote neovascularization. Cathodal currents can also dampen the inflammatory cascade and facilitate the shift of macrophages from the M1 to the pro-healing M2 phenotype. The advent of nanogenerators, conductive hydrogels, and wireless “smart” bandages is gradually freeing ES from hard-wired leads, paving the way for home-based, closed-loop wound care. This review summarizes the latest mechanistic insights and device innovations, providing a reference for future clinical optimization and multicenter trials.

## Linked entities

- **Proteins:** HIF1A (hypoxia inducible factor 1 subunit alpha), VEGFA (vascular endothelial growth factor A)

## Full-text entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** DFU (MESH:D017719), ischemia (MESH:D007511), diabetes (MESH:D003920), inflammatory (MESH:D007249)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12819206/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12819206/full.md

## References

83 references — full list in the complete paper: https://tomesphere.com/paper/PMC12819206/full.md

---
Source: https://tomesphere.com/paper/PMC12819206